Ongoing Studies
Fachnetzwerk Infektionen : Study master study protocol for the cohort of the specialist network infectious diseases
Reset MDR
: A Randomized controlled open-label phase 2 trial assessing the efficacy and safety of two-dosing regimens of frozen encapsulated fecal microbiota transfer products with or without an individualized donor selection approach in decolonizing carriers of multi-drug resistant Enterobacteriaceae
- EU Trial number: 2024-519748-34-00
SNAP Network Adaptive Platform : SNAP registry study: registration of patients with bloodstream infections with the bacterium staphylococcus aureus. Network Adaptive Platform.
Pfizer : An interventional efficacy and safety, phase 3, randomized, double-blind, 3-arm study to investigate ibuzatrelvir in adults with symptomatic covid-19 who are severely immunocompromised - EU Trial Number:2024-517671-21-00
MDR – TB- Kohorte : Building and evaluation of a competence network to improve therapy adherence for the sustainable enhancement of treatment outcomes in multidrug-resistant tuberculosis in Germany – No1Lost, Capnetz Stiftung
MVA_MERS-S Phase 1b Longterm Follow-up
TherVacB Phase 1a Trial NCT05727267
We also conduct clinical trials in collaboration with the Bernhard Nocht Center for Clinical Trials ( BNCCT ).
Completed Studies
MVA-MERS-S Phase 1b Vaccine Trial (NCT04119440)
CMVictory Phase 3 Trial (NCT05085366)
MVA-SARS-CoV-2-ST Phase 1b Trial (NCT04895449)
rVSV-ZEBOV (NCT02283099)
MVA-SARS-2-S (NCT04569383)
MVA-MERS-S (NCT04119440)
INFLIXCOVID UK Jena (NCT04922827)
Study to Evaluate the Safety and Antiviral Efficacy of Remdesivir (GS-5734™) in Participants with Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care (NCT04292730) Link
Study to Evaluate the Safety and Antiviral Efficacy of Remdesivir (GS-5734™) in Participants with Severe Coronavirus Disease (COVID-19) (NCT04292899) Link